EduCon Virtual 2021 Learning Objectives
Pharmacists AND Technicians
(Note: for activity -020- objectives for technicians are different)

February 4
ACPE #0129-9999-21-014-H03-P 0.1 CEU
ACPE #0129-9999-21-014-H03-T 0.1 CEU

Knowledge-based activity
The APC Code of Ethics: Ensuring Your Reputation and Legal Standing
Jon Pritchett, PharmD., R.Ph., BCSCP
At the completion of this activity, the participant will be able to:
1. review *The Pharmacy Compounding Professional’s Code of Ethics* from Alliance for Pharmacy Compounding;
2. recognize examples of ethical considerations that compounding pharmacists may encounter; and
3. discuss best practice recommendations for ensuring compliance with the Responsibilities to One’s Patients, Self, Colleagues and Profession listed in the Code of Ethics.
4. recognize that most state pharmacy laws have some language dealing with unprofessional conduct; and
5. explain how unprofessional conduct is often the result of ethical lapses, which can be avoided by carefully adhering to the code of ethics.

ACPE #0129-9999-21-015-H06-P 0.1 CEU
ACPE #0129-9999-21-015-H06-T 0.1 CEU

Knowledge-based activity
COVID Vaccine: Best Practices for Pharmacies
Tracy Dabbs, PharmD
At the completion of this activity, the participant will be able to:
1. discuss the details of the COVID-19 vaccine use process (e.g., provider agreement, ordering, storage, administration);
2. identify who is eligible for COVID-19 vaccine;
3. review guidance for billing of COVID-19 Vaccine; and
4. summarize vaccine fraud and abuse guidelines, and the penalties for violating provider agreements.

ACPE #0129-9999-21-016-H07-P 0.1 CEU
ACPE #0129-9999-21-016-H07-T 0.1 CEU

Knowledge-based activity
What’s That? Answering Your Questions About Historical Formulations
Lisa Ashworth, BSPharm, R.Ph.; Rich Moon, R.Ph., PharmD; Erik Tosh, DPh
At the completion of this activity, the participant will be able to:
1. identify some historical formulations by name(s), and not by name;
2. describe how they may have received their names;
3. recognize and verify there may be several formulations for a named formulation;
4. demonstrate knowledge of the clinical relevance of the formulations; and
5. describe a process for determining legal labeling.

ACPE #0129-9999-21-017-H07-P 0.1 CEU
ACPE #0129-9999-21-017-H07-T 0.1 CEU

Knowledge-based activity
Quick Tours: HCG, Peptides, e-Prescribing, Insanitary Conditions, BUDs and USP, and More!
Kim Kieffer, CPhT; Michelle Wong, R.Ph.; Karla Palmer; Tenille Davis, PharmD, R.Ph.; Matt Martin, PharmD
At the completion of this activity, the participant will be able to:
1. review the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) that requires a marketing application for a “biological product,” and how it affects certain bulk substances that had previously been used in compounding;

2. explain how the BPCI Act limits compounding activities for drug shortages and may disrupt patient access to certain drugs;

3. identify the basics of the BPCIA with respect to compounding;

4. recognize whether compounded formulations are peptides that have transitioned to biologics;

5. explain how to determine whether there is an ability to address the transition from drugs to biological products for certain products;

6. review the timeline of USP’s updates to Chapters 795 and 797;

7. discuss the 2019 appeal and 2020 decision to delay implementation by USP;

8. recognize what’s wrong with the proposed BUDs;

9. explain what APC suggests in place of the proposed BUDs;

10. apply the FDA’s Insanitary Conditions Guidance to compounding practice; and

11. review examples of Insanitary Conditions.

**February 5**

ACPE #0129-9999-21-018-H04-P 0.1 CEU
ACPE #0129-9999-21-018-H04-T 0.1 CEU

*Knowledge-based activity*

**Why the Math Matters: Calculations & Legal Risks**  
*Brenda Jensen, CPhT; Wendy Harris; Kristen Jones, R.Ph.*

At the completion of this activity, the participant will be able to:

1. recognize when to make adjustments to quantity based on a chemical’s assay and/or water content;

2. identify when salt form conversions are required;

3. explain how to calculate Minimum Accurate Weighable Quantity (MAWQ);

4. explain liability factors in pharmacy claims associated with levothyroxine and liothyronine;

5. evaluate costs associated with pharmacy claims involving compounded thyroid medications; and

6. discuss practical risk management techniques to prevent or mitigate pharmacy liability exposures associated with compounding medications.

ACPE #0129-9999-21-019-H05-P 0.1 CEU
ACPE #0129-9999-21-019-H05-T 0.1 CEU

*Knowledge-based activity*

**Pharmacovigilance: Preventing Adverse Events**  
*Sara Rogers, PharmD, BCPS*

At the completion of this activity, the participant will be able to:

1. discuss key issues related to adverse drug events;

2. describe the history and timeline of regulatory oversight for compounding;

3. review a case example of compounded hormone pellets; and

4. demonstrate best practices to prevent and report adverse events for compounded medications.

ACPE #0129-9999-21-020-H07-P 0.1 CEU
ACPE #0129-9999-21-020-H07-T 0.1 CEU

*Application-based activity*

**From Aliquots to Zoonotics: The A to Z of Developing Pharmacy Compounding Formulations**  
*Mindy Cormier, PharmD, R.Ph.*

At the completion of this activity, the pharmacist participant will be able to:
1. evaluate the appropriateness of a specific compounded formulation in relation to the therapeutic intent, requested dosage form, and patient demographic;
2. differentiate formulation-specific factors that need to be considered when developing a non-sterile preparation vs. sterile preparation;
3. assess the physiochemical properties of all APIs in a single preparation to determine the necessity of specific excipients for stability;
4. explain the beyond-use date applied to a compounded preparation as it pertains to the applicability of published literature studies and USP’s default BUD (beyond use date) standards; and
5. identify any special considerations that warrant patient counseling as it pertains to administration and storage.

At the completion of this activity, the pharmacy technician participant will be able to:
1. evaluate the appropriateness of a specific compounded formulation in relation to the therapeutic intent, requested dosage form, and patient demographic;
2. differentiate formulation-specific factors that need to be considered when developing a non-sterile preparation vs. sterile preparation;
3. assess the physiochemical properties of all APIs in a single preparation to determine the necessity of specific excipients for stability; and
4. explain the beyond-use date applied to a compounded preparation as it pertains to the applicability of published literature studies and USP’s default BUD (beyond use date) standards.

ACPE #0129-9999-21-021-H07-P  0.1 CEU
ACPE #0129-9999-21-021-H07-T  0.1 CEU

Knowledge-based activity

What’s in It? All About Excipients
A.J. Day, PharmD
At the completion of this activity, the participant will be able to:
1. identify key regulatory differences between API (active pharmaceutical ingredient) and excipients;
2. explain how to analyze characteristics of excipients to determine appropriateness with the intended use of the final formula; and
3. describe mechanisms of drug degradation, and classes of excipients to protect against them.

ACPE #0129-9999-21-022-H04-P  0.1 CEU
ACPE #0129-9999-21-022-H04-T  0.1 CEU

Knowledge-based activity

Works for Me: 6 Great Ideas for Doing It Better, Cheaper, Faster
Jason Humphrey; Jennifer Burch, PharmD, R.Ph.; Shawn Crane, CPhT; Jim Hrncir, R.Ph.; Joseph Navarra, R.Ph., Michelle Moser, R.Ph.
At the completion of this activity, the participant will be able to:
1. describe the patient intake process;
2. describe the basket system for work flow;
3. describe the notification process;
4. identify prescribers that have reduced waiting room capacity;
5. discuss how to reduce Covid-19 Exposure risk in prescribers’ offices;
6. recognize ways to increase office visit capacity now;
7. describe how to help increase prescribers’ office visit capacity in the future; and
8. explain how to put together patient and prescriber seminars that will engage your audience, lead to enhanced visibility in the community, and increase profit margins.